Stock comparison
Moderna, Inc. is 12.3x more valuable than Vericel Corp by market capitalization ($30.38 B vs $2.47 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 12.3x more valuable than Vericel Corp by market capitalization ($30.38 B vs $2.47 B).
Market value leader
MRNA
Moderna, Inc. is 12.3x more valuable than Vericel Corp by market capitalization ($30.38 B vs $2.47 B).
Revenue leader
MRNA
VCEL: $276.26M vs MRNA: $1.94B.
Profit leader
VCEL
VCEL: $16.52M vs MRNA: -$2.82B.
Margin leader
VCEL
VCEL: 6.0% vs MRNA: -145.2% net margin.
| Metric | VCEL | MRNA |
|---|---|---|
| Market cap | $2.47 B | $30.38 B |
| US-listed rank | #1991 | #461 |
| Revenue (latest FY) | $276.26M | $1.94B |
| Net income (latest FY) | $16.52M | -$2.82B |
| Net margin | 6.0% | -145.2% |
| P/E (trailing FY) | 149.4x | - |
| SEC filings | 1,674 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 12.3x more valuable than Vericel Corp by market capitalization ($30.38 B vs $2.47 B).
In their latest fiscal years, Vericel Corp reported $276.26M in revenue while Moderna, Inc. reported $1.94B.
Full pages: Vericel Corp and Moderna, Inc., or browse the full rankings.